Sugi Predict

Sugi Predict / Compounds / SCHEMBL578232

SCHEMBL578232

SCHEMBL578232

COc1ccc2c(c1)C(=O)C(=O)N2Cc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PARK7 Q99497 1/20 0.76
▸ CHRM5 P08912 7/20 0.69
▸ ALDH1A1 P00352 3/20 0.66
▸ ALDH2 P05091 3/20 0.66
▸ ALDH3A1 P30838 3/20 0.66
▸ CA12 O43570 2/20 0.64
▸ CA1 P00915 2/20 0.64
▸ CA2 P00918 2/20 0.64
▸ CA9 Q16790 2/20 0.64
▸ CHRM1 P11229 1/20 0.61
▸ CES1 P23141 1/20 0.61
▸ CASP3 P42574 2/20 0.60
▸ CASP1 P29466 1/20 0.59
▸ CASP4 P49662 1/20 0.59
▸ CASP7 P55210 1/20 0.59
▸ CASP9 P55211 1/20 0.59
▸ CASP6 P55212 1/20 0.59
▸ CASP8 Q14790 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29406370 1.00 PARK7 (0.76) PARK7CHRM5ALDH1A1ALDH2ALDH3A1
SCHEMBL3014022 0.89 CHRM5 (0.67) PARK7CHRM5ALDH1A1ALDH2ALDH3A1
SCHEMBL5429061 0.86 CHRM5 (0.72) PARK7CHRM5ALDH1A1ALDH3A1CA12
SCHEMBL9094351 0.84 PARK7 (0.69) PARK7ALDH1A1ALDH3A1
SCHEMBL14740713 0.84 CHRM5 (0.73) PARK7CHRM5ALDH1A1ALDH2ALDH3A1
SCHEMBL28365901 0.83 PARK7 (0.55) PARK7CHRM5ALDH1A1ALDH2ALDH3A1
SCHEMBL29460856 0.83 CASP3 (0.76) CHRM5ALDH1A1ALDH2ALDH3A1CA12
SCHEMBL2305451 0.83 CASP3 (0.76) CHRM5ALDH1A1ALDH2ALDH3A1CA12
SCHEMBL18955277 0.82 PARK7 (0.63) PARK7CHRM5ALDH1A1ALDH3A1CA12
SCHEMBL4597561 0.82 ALDH1A1 (0.74) PARK7CHRM5ALDH1A1ALDH2ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS INC (US) 2026-04-23 — — US disclosed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 — — WO disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 — — WO disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 — — EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
WO-2009123080-A1 INDOLINONE COMPOUND アステラス製薬株式会社 (JP) 2009-10-08 — — WO disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 — — US disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 — — US disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 — — US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 — — US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 — — US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 — — US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 — — US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 — — EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PARK7 3747/4885CHRM5 4088/4885ALDH1A1 2205/4885
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PARK7 1996/4885CHRM5 4877/4885ALDH1A1 2211/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 PARK7 1996/4885CHRM5 4877/4885ALDH1A1 2211/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 PARK7 1996/4885CHRM5 4877/4885ALDH1A1 2211/4885
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents CBR1, CBR3, SCN8A PARK7 445/4885CHRM5 245/4885ALDH1A1 2087/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PARK7 2105/4885CHRM5 4879/4885ALDH1A1 2066/4885
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 PARK7 4488/4885CHRM5 1591/4885ALDH1A1 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.